Benjamin M Scirica1, Deepak L Bhatt1, Eugene Braunwald1, Itamar Raz2, Matthew A Cavender1, KyungAh Im1, Ofri Mosenzon2, Jacob A Udell3, Boaz Hirshberg4, Pia S Pollack4, Ph Gabriel Steg5, Petr Jarolim6, David A Morrow1. 1. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel. 3. Women's College Research Institute and Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada4Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. 4. AstraZeneca Research and Development, Gaithersburg, Maryland. 5. National Heart and Lung Institute, Imperial College, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, London, England7INSERM U-1148, Département Hospitalo-Universitaire FIRE (Fibrosis-Inflammation-Remodelling), Université Paris-Diderot, Paris, France8Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France. 6. Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
IMPORTANCE: Cardiac biomarkers provide insights into pathophysiologic processes and offer an attractive strategy for the assessment of cardiovascular risk. OBJECTIVE: To assess the incremental prognostic value of biomarkers that reflect different pathophysiologic processes in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 is a randomized, double-blind, placebo-controlled clinical trial that evaluated the safety of saxagliptin vs placebo in 16 492 outpatients with type 2 diabetes with overt cardiovascular disease (CVD) or multiple risk factors. In this secondary analysis, widely used biomarkers were evaluated to ascertain whether they would provide incremental prognostic value in the risk stratification. Median follow-up was 2.1 years (interquartile range, 1.8-2.3 years). The study was performed from May 10, 2010, to June 15, 2013. INTERVENTIONS: Randomization to saxagliptin vs placebo in addition to standard care. MAIN OUTCOMES AND MEASURES: Concentrations of high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein were analyzed continuously and by established cut points. Cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization for heart failure (HF) were adjudicated by a blinded events committee. RESULTS: Of the 16 492 patients, 5455 (33.1%) were female and 11 037 (66.9%) were male. Mean (SD) age was 65.0 (8.5) years (range, 39-99 years). Baseline biomarkers were measured in 12 310 patients. Elevated levels of each biomarker were associated significantly with increased risk for all cardiovascular end points. When added to clinical variables, biomarkers significantly improved the discrimination and appropriate reclassification of risk. Elevated high-sensitivity troponin T was associated with an increased risk of cardiovascular death (adjusted hazard ratio [AHR], 3.07; 95% CI, 2.35-4.02; P < .001), myocardial infarction (AHR, 2.13; 95% CI, 1.69-2.67; P < .001), and hospitalization for HF (AHR, 3.85; 95% CI, 2.82-5.27; P < .001). Elevated N-terminal pro-B-type natriuretic peptide was also associated with an increased risk of cardiovascular death (AHR, 3.09; 95% CI, 2.46-3.89; P < .001), myocardial infarction (AHR, 1.95; 95% CI, 1.51-2.53; P < .001), and hospitalization for HF (AHR, 3.92; 95% CI, 3.11-4.92; P < .001). Elevated high-sensitivity C-reactive protein was more weakly associated with an increased risk of cardiovascular death (AHR, 1.49; 95% CI, 1.22-1.82; P < .001) and hospitalization for HF (AHR, 1.47; 95% CI, 1.20-1.81; P < .001). Consistent results were seen in patients with or without established CVD. CONCLUSIONS AND RELEVANCE: A substantial proportion of patients with stable type 2 diabetes with established CVD or multiple clinical risk factors have evidence of ongoing myocardial injury, hemodynamic stress, or systemic inflammation. Biomarker risk stratification thus challenges the traditional differentiation between primary and secondary prevention based simply on clinical history. Strategies to improve risk stratification in patients with type 2 diabetes, with or without CVD, should consider incorporation of biomarker data into standard risk algorithms. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01107886.
IMPORTANCE: Cardiac biomarkers provide insights into pathophysiologic processes and offer an attractive strategy for the assessment of cardiovascular risk. OBJECTIVE: To assess the incremental prognostic value of biomarkers that reflect different pathophysiologic processes in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 is a randomized, double-blind, placebo-controlled clinical trial that evaluated the safety of saxagliptin vs placebo in 16 492 outpatients with type 2 diabetes with overt cardiovascular disease (CVD) or multiple risk factors. In this secondary analysis, widely used biomarkers were evaluated to ascertain whether they would provide incremental prognostic value in the risk stratification. Median follow-up was 2.1 years (interquartile range, 1.8-2.3 years). The study was performed from May 10, 2010, to June 15, 2013. INTERVENTIONS: Randomization to saxagliptin vs placebo in addition to standard care. MAIN OUTCOMES AND MEASURES: Concentrations of high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein were analyzed continuously and by established cut points. Cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization for heart failure (HF) were adjudicated by a blinded events committee. RESULTS: Of the 16 492 patients, 5455 (33.1%) were female and 11 037 (66.9%) were male. Mean (SD) age was 65.0 (8.5) years (range, 39-99 years). Baseline biomarkers were measured in 12 310 patients. Elevated levels of each biomarker were associated significantly with increased risk for all cardiovascular end points. When added to clinical variables, biomarkers significantly improved the discrimination and appropriate reclassification of risk. Elevated high-sensitivity troponin T was associated with an increased risk of cardiovascular death (adjusted hazard ratio [AHR], 3.07; 95% CI, 2.35-4.02; P < .001), myocardial infarction (AHR, 2.13; 95% CI, 1.69-2.67; P < .001), and hospitalization for HF (AHR, 3.85; 95% CI, 2.82-5.27; P < .001). Elevated N-terminal pro-B-type natriuretic peptide was also associated with an increased risk of cardiovascular death (AHR, 3.09; 95% CI, 2.46-3.89; P < .001), myocardial infarction (AHR, 1.95; 95% CI, 1.51-2.53; P < .001), and hospitalization for HF (AHR, 3.92; 95% CI, 3.11-4.92; P < .001). Elevated high-sensitivity C-reactive protein was more weakly associated with an increased risk of cardiovascular death (AHR, 1.49; 95% CI, 1.22-1.82; P < .001) and hospitalization for HF (AHR, 1.47; 95% CI, 1.20-1.81; P < .001). Consistent results were seen in patients with or without established CVD. CONCLUSIONS AND RELEVANCE: A substantial proportion of patients with stable type 2 diabetes with established CVD or multiple clinical risk factors have evidence of ongoing myocardial injury, hemodynamic stress, or systemic inflammation. Biomarker risk stratification thus challenges the traditional differentiation between primary and secondary prevention based simply on clinical history. Strategies to improve risk stratification in patients with type 2 diabetes, with or without CVD, should consider incorporation of biomarker data into standard risk algorithms. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01107886.
Authors: David D Berg; Ahmed A Kolkailah; Ashish Sarraju; Anne Marie Kerchberger; Mahmoud Eljalby; Darren K McGuire Journal: Curr Diab Rep Date: 2021-11-06 Impact factor: 4.810
Authors: Benjamin M Scirica; Ofri Mosenzon; Deepak L Bhatt; Jacob A Udell; Ph Gabriel Steg; Darren K McGuire; KyungAh Im; Estella Kanevsky; Christina Stahre; Mikaela Sjöstrand; Itamar Raz; Eugene Braunwald Journal: JAMA Cardiol Date: 2018-02-01 Impact factor: 14.676
Authors: Brian A Bergmark; Benjamin M Scirica; Ph Gabriel Steg; Christina L Fanola; Yared Gurmu; Ofri Mosenzon; Avivit Cahn; Itamar Raz; Deepak L Bhatt Journal: Eur Heart J Date: 2018-06-21 Impact factor: 29.983
Authors: Samuel S Gidding; Fida Bacha; Petter Bjornstad; Lorraine E Levitt Katz; Lynne L Levitsky; Jane Lynch; Jeanie B Tryggestad; Ruth S Weinstock; Laure El Ghormli; Joao A C Lima Journal: J Pediatr Date: 2018-01 Impact factor: 4.406
Authors: Matthew W Segar; Muthiah Vaduganathan; Kershaw V Patel; Darren K McGuire; Javed Butler; Gregg C Fonarow; Mujeeb Basit; Vaishnavi Kannan; Justin L Grodin; Brendan Everett; Duwayne Willett; Jarett Berry; Ambarish Pandey Journal: Diabetes Care Date: 2019-09-13 Impact factor: 19.112